BALTIMORE / Mar 05, 2024 / Business Wire / MyMD Pharmaceuticals, Inc.® ( Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 4, 2024 informing the Company that it has regained compliance with the... Read More

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 BALTIMORE / Feb 13, 2024 / Business Wire / MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a... Read More

Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA BALTIMORE / Dec 06, 2023 / Business Wire / MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that its... Read More

Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments BALTIMORE / Oct 19, 2023 /... Read More

Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study of MYMD-1 in sarcopenia, an age-related frailty disorder BALTIMORE / Oct 04, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company... Read More

Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of a $41 billion industry Acceptance follows statistically significant Phase 2 data in sarcopenia showing MYMD-1 reduced TNF-α and other inflammatory markers common to RA, while demonstrating safety and tolerability MyMD now... Read More

BALTIMORE / Aug 02, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this... Read More

MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets... Read More

Currently, there are no FDA-approved treatments for sarcopenia/frailty MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate MYMD-1 ® BALTIMORE, MD / Apr 12, 2023 / Business Wire / MyMD Pharmaceuticals, Inc . ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and... Read More

BALTIMORE / Mar 20, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data from a preclinical study of investigational, oral TNF-α inhibitor MYMD-1® at the 2023 Society of Toxicology Annual Meeting (SOT) in... Read More

BALTIMORE / Mar 02, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review and determined that investigational cannabinoid... Read More

BALTIMORE / Feb 28, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, announced that preclinical data from a study, conducted in partnership with Charles River Laboratories International, Inc., has been accepted for... Read More

BALTIMORE / Feb 21, 2023 / Business Wire / MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has executed a securities purchase agreement to raise gross proceeds of approximately $15 million in a registered direct... Read More